Increased cardiac myocyte PDE5 levels in human and murine pressure overload hypertrophy contribute to adverse LV remodeling - Wikidata - wikimedia - TriplyDB

Increased cardiac myocyte PDE5 levels in human and murine pressure overload hypertrophy contribute to adverse LV remodeling

Increased cardiac myocyte PDE5 levels in human and murine pressure overload hypertrophy contribute to adverse LV remodeling

http://www.wikidata.org/entity/Q34634339

about

Therapeutic potential of PDE modulation in treating heart disease Long-term effect of sildenafil on echocardiographic parameters in dogs with asymptomatic myxomatous mitral valve degeneration.Sex, drugs, and trial design: sex influences the heart and drug responses PDE5 inhibitor efficacy is estrogen dependent in female heart disease.Myosin phosphatase isoforms and related transcripts in the pig coronary circulation and effects of exercise and chronic occlusion.Right ventricular cyclic nucleotide signaling is decreased in hyperoxia-induced pulmonary hypertension in neonatal mice.Decreased Soluble Guanylate Cyclase Contributes to Cardiac Dysfunction Induced by Chronic Doxorubicin Treatment in Mice.Cardiac Phosphodiesterases and Their Modulation for Treating Heart Disease.Doxorubicin-induced chronic dilated cardiomyopathy-the apoptosis hypothesis revisited.

P2860

Q27005761-36E26E34-1E08-4DB5-8259-1FC9873FDD55 Q33594036-2C8248ED-5B95-468F-8438-00BD506A6340 Q33872473-0C55B2C7-FCCB-4E21-B531-EB5D1CF07F35 Q33872491-0911FD51-E475-4D6D-9F07-A3616A09B4C4 Q34051651-6CE3B2FC-5E02-47F8-AAE8-6F3B68AE2D26 Q35749616-7E37111B-D4DF-47C0-90B3-1288601264A2 Q37613120-A51C74C7-F776-402F-88AC-F55C9510533D Q38992600-333E1F91-DFD9-4549-8663-94413833CBD9 Q39033784-8EAB5513-99DE-40C7-BDD4-2824CBBFC62C

P2860

Increased cardiac myocyte PDE5 levels in human and murine pressure overload hypertrophy contribute to adverse LV remodeling

http://www.wikidata.org/entity/Q34634339

description

2013 nî lūn-bûn

@nan

2013 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի մարտին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Increased cardiac myocyte PDE5 ...... ibute to adverse LV remodeling

@ast

Increased cardiac myocyte PDE5 ...... ibute to adverse LV remodeling

@en

Increased cardiac myocyte PDE5 ...... ibute to adverse LV remodeling

@nl

type

label

Increased cardiac myocyte PDE5 ...... ibute to adverse LV remodeling

@ast

Increased cardiac myocyte PDE5 ...... ibute to adverse LV remodeling

@en

Increased cardiac myocyte PDE5 ...... ibute to adverse LV remodeling

@nl

prefLabel

Increased cardiac myocyte PDE5 ...... ibute to adverse LV remodeling

@ast

Increased cardiac myocyte PDE5 ...... ibute to adverse LV remodeling

@en

Increased cardiac myocyte PDE5 ...... ibute to adverse LV remodeling

@nl

P1433

Q34634339-200CCDC2-D5FE-49BE-8101-2D295A3CE0F2

P1476

Q34634339-DDE570E8-AA8D-4171-B119-DFABB4F94709

P2093

Q34634339-01EEE891-661C-4CE1-8692-7B6580B4D5D6

Q34634339-0C9D745F-5E45-42C8-88C2-B3A4C53FD045

Q34634339-4B922636-CD9F-4C34-9995-1A6127FF553B

Q34634339-6D8992AB-2475-44DA-B40E-238943C9099A

Q34634339-82B49D79-55E8-4598-A453-C8BF885ACBFE

Q34634339-8655EDE3-E251-4533-BE35-14F8F94C672A

Q34634339-9BF5D5D9-FF3B-4BAF-B2AB-AC12F6D4B491

Q34634339-9DA266D2-F776-4BA5-9B04-9603D1677684

Q34634339-AD776531-F4B3-4E85-8789-6DD76B203E01

Q34634339-BD6AEF5D-BC2A-42A6-B2C3-B002D4F3D7FD

P2860

Q34634339-038062C3-AC9F-407A-8AA5-D7D50200BBF5

Q34634339-05915483-EC44-4FBD-A177-B457FE898CEA

Q34634339-0B063659-4C85-498E-997E-580C2CFFE5F4

Q34634339-0B2B0B32-A17B-4B98-812F-36821F192046

Q34634339-21648973-E865-4D48-AF8E-2F50A1FCE4BE

Q34634339-44B33951-6293-4E07-9952-77FCD2E93CD5

Q34634339-5C42476B-7C00-4C9D-81D3-BF366430502C

Q34634339-627E4694-07A4-47CC-953C-FB9E5B80876A

Q34634339-6B3CC6CF-F157-443D-B27A-0F0B36EB7E96

Q34634339-73594DAD-C18D-4D8A-BECE-1EEEE7473FCD

P304

Q34634339-76C72FF2-ACBB-4503-BA83-FD1C5E753A9D

P31

Q34634339-41D3A160-68FA-48C5-823E-5757C6BFEDC7

P356

Q34634339-D4C8F30A-3E5B-427F-9C09-B5D56D636D05

P407

Q34634339-2D692004-8FB6-4555-A4E9-59527BB514B1

P433

Q34634339-F0622587-DACF-436C-A902-70A195414618

P478

Q34634339-69B9E54B-A8EE-4421-8BAC-48973FDDDD81

P50

Q34634339-78DA2D20-E6DD-48D4-BC2D-5F9E50F74669

Q34634339-B5496C4D-EAF4-4D1E-97BC-DBABCAB19F61

Q34634339-C6A662EB-657A-41AC-B113-9D4FC7D51AB4

Q34634339-CE75D120-8A35-4066-85DC-EEDAF767E3F5

Q34634339-FE27D7B0-8D79-4A89-AF38-C25962816995

P577

Q34634339-9EE8DDBD-8F3C-4699-A1EB-786F0893F2D8

P5875

Q34634339-DC2145CF-3B10-4910-BC53-C99B7F91D0B6

P698

Q34634339-1BBB6A17-6A49-41D8-8A2E-C8F0C6BE0881

P932

Q34634339-FBA36483-BD08-40F7-9631-E7FD96D5D563

P356

JOURNAL.PONE.0058841

P1433

P1476

Increased cardiac myocyte PDE5 ...... ibute to adverse LV remodeling

@en

P2093

Agnes Balogh

http://www.w3.org/2001/XMLSchema#string

Erik Verbeken

http://www.w3.org/2001/XMLSchema#string

Giulia Coppiello

http://www.w3.org/2001/XMLSchema#string

Hadewich Hermans

http://www.w3.org/2001/XMLSchema#string

Hilde Gillijns

http://www.w3.org/2001/XMLSchema#string

Jan D'hooge

http://www.w3.org/2001/XMLSchema#string

Jozef Bartunek

http://www.w3.org/2001/XMLSchema#string

Kenneth D Bloch

http://www.w3.org/2001/XMLSchema#string

Marie Christine Herregods

http://www.w3.org/2001/XMLSchema#string

Marijke Pellens

http://www.w3.org/2001/XMLSchema#string

P2860

Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method

Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility

Ventricular phosphodiesterase-5 expression is increased in patients with advanced heart failure and contributes to adverse ventricular remodeling after myocardial infarction in mice.

Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study.

Oxidative stress regulates left ventricular PDE5 expression in the failing heart

Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure.

Cyclic guanosine monophosphate signaling and phosphodiesterase-5 inhibitors in cardioprotection.

Cyclic nucleotide phosphodiesterase PDE1C1 in human cardiac myocytes.

Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group.

Effects of phosphodiesterase type 5 inhibition on systemic and pulmonary hemodynamics and ventricular function in patients with severe symptomatic aortic stenosis

P304

e58841

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0058841

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-03-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236078851

http://www.w3.org/2001/XMLSchema#string

P698

23527037

http://www.w3.org/2001/XMLSchema#string

P932

3601083

http://www.w3.org/2001/XMLSchema#string